Background International migrants experience increased mortality from hepatocellular carcinoma compared to host populations, largely due to undetected chronic hepatitis B infection (HBV). We conducted a systematic review of the seroprevalence of chronic HBV and prior immunity in migrants arriving in low HBV prevalence countries to identify those at highest risk in order to guide disease prevention and control strategies. Methods and Findings Medline, Medline In-Process, EMBASE and the Cochrane Database of Systematic Reviews were searched. Studies that reported HBV surface antigen or surface antibodies in migrants were included. The seroprevalence of chronic HBV and prior immunity were pooled by region of origin and immigrant class, using a random-effects model. A random-effects logistic regression was performed to explore heterogeneity. The number of chronically infected migrants in each immigrant-receiving country was estimated using the pooled HBV seroprevalences and country-specific census data. A total of 110 studies, representing 209,822 immigrants and refugees were included. The overall pooled seroprevalence of infection was 7.2% (95% CI: 6.3%–8.2%) and the seroprevalence of prior immunity was 39.7% (95% CI: 35.7%–43.9%). HBV seroprevalence differed significantly by region of origin. Migrants from East Asia and Sub-Saharan Africa were at highest risk and migrants from Eastern Europe were at an intermediate risk of infection. Region of origin, refugee status and decade of study were independently associated with infection in the adjusted random-effects logistic model. Almost 3.5 million migrants (95% CI: 2.8–4.5 million) are estimated to be chronically infected with HBV. Conclusions The seroprevalence of chronic HBV infection is high in migrants from most world regions, particularly among those from East Asia, Sub-Saharan Africa and Eastern Europe, and more than 50% were found to be susceptible to HBV. Targeted screening and vaccination of international migrants can become an important component of HBV disease control efforts in immigrant-receiving countries.
References
[1]
Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, et al. (2004) Global epidemiology of hepatitis B virus. J Clin Gastroenterol 38: S158–168.
[2]
Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97–107.
[3]
Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, et al. (2008) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57: 1–20.
[4]
Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, et al. (2005) A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 54: 1–31.
[5]
Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, et al. (2006) A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 55: 1–33.
[6]
International Organization for Migration (2010) Facts and Figures. Available: http://www.iom.int/jahia/Jahia/about-mig？ration/facts-and-figures/lang/en Accessed 2011 Jul 05.
[7]
McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF (2001) International trends and patterns of primary liver cancer. Int J Cancer 94: 290–296.
[8]
McGlynn KA, London WT (2011) The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 15: 223–243.
[9]
McDermott S, Desmeules M, Lewis R, Gold J, Payne J, et al. (2011) Cancer incidence among Canadian immigrants, 1980–1998: results from a national cohort study. J Immigr Minor Health 13: 15–26.
[10]
Wong R, Corley DA (2008) Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med 121: 525–531.
[11]
Haworth EA, Soni Raleigh V, Balarajan R (1999) Cirrhosis and primary liver cancer amongst first generation migrants in England and Wales. Ethn Health 4: 93–99.
[12]
Bouchardy C, Wanner P, Parkin DM (1995) Cancer mortality among sub-Saharan African migrants in France. Cancer Causes Control 6: 539–544.
[13]
Grulich AE, McCredie M, Coates M (1995) Cancer incidence in Asian migrants to New South Wales, Australia. Br J Cancer 71: 400–408.
[14]
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
[15]
Levine OS, Vlahov D, Nelson KE (1994) Epidemiology of hepatitis B virus infections among injecting drug users: seroprevalence, risk factors, and viral interactions. Epidemiol Rev 16: 418–436.
[16]
MacKellar DA, Valleroy LA, Secura GM, McFarland W, Shehan D, et al. (2001) Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 91: 965–971.
[17]
World Bank (2011) How we Classify Countries. Available: http://data.worldbank.org/about/country-？classifications/country-and-lending-grou？ps Accessed 2011 Feb 11.
[18]
Fleiss JL (1993) The statistical basis of meta-analysis. Stat Methods Med Res 2: 121–145.
[19]
Rucker G, Schwarzer G, Carpenter J, Olkin I (2009) Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. Stat Med 28: 721–738.
[20]
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.
[21]
Schwarzer G (2007) meta: An R Package for Meta-Analysis. R News 7: 40–45.
[22]
Bates D, Maechler M, Bolker B (2011) lme4: Linear mixed-effects models using S4 classes. R package version 0.999375–42.
[23]
Centers for Disease Control and Prevention (2011) Hepatitis B. 2012 Yellow Book. New York: Oxford University Press. 640 p.
[24]
Merrill RM, Hunter BD (2011) Seroprevalence of markers for hepatitis B viral infection. Int J Infect Dis 15: e78–121.
[25]
World Health Organization (2008) Hepatitis B. Fact Sheet No. 204. Available: http://www.who.int/mediacentre/factsheet？s/fs204/en/. Accessed 2011 May 17.
[26]
Hutton DW, Tan D, So SK, Brandeau ML (2007) Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med. 147: 460–469.
[27]
Veldhuijzen IK, Toy M, Hahne SJ, De Wit GA, Schalm SW, et al. (2010) Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 138: 522–530.
[28]
Eckman MH, Kaiser TE, Sherman KE (2011) The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States. Clin Infect Dis 52: 1294–1306.
[29]
Wong WW, Woo G, Jenny Heathcote E, Krahn M (2011) Cost effectiveness of screening immigrants for hepatitis B. Liver Int. 31: 1179–1190.
[30]
Connolly MA, Gayer M, Ryan MJ, Salama P, Spiegel P, et al. (2004) Communicable diseases in complex emergencies: impact and challenges. Lancet 364: 1974–1983.
[31]
Gayer M, Legros D, Formenty P, Connolly MA (2007) Conflict and emerging infectious diseases. Emerg Infect Dis 13: 1625–1631.
[32]
Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, et al. (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378: 571–583.
[33]
DesMeules M, Gold J, McDermott S, Cao Z, Payne J, et al. (2005) Disparities in mortality patterns among Canadian immigrants and refugees, 1980–1998: results of a national cohort study. J Immigr Health 7: 221–232.
[34]
European Centre for Disease Control and Prevention (2010) Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Available: http://ecdc.europa.eu/en/publications/Pu？blications/TER_100914_Hep_B_C%20_EU_neig？hbourhood.pdf. Accessed 2012 Jul 10.
[35]
Greenaway C, Narasiah L, Plourde P, Ueffing E, Deschenes M, et al. (2011) Hepatitis B: Evidence Review for Newly Arriving Immigrants and Refugees. CMAJ 183: E847–E851.
[36]
Health Protection Agency (2011) Migrant Health Guide. Available: http://www.hpa.org.uk/MigrantHealthGuide？/Accessed 2012 Jul 10.
[37]
Australian Society for Infectious Diseases (2009) Diagnosis, management and prevention of infections in recently arrived refugees. Sydney: Dreamweaver Publishing Pty Ltd. 61 p.
[38]
Rein DB, Lesesne SB, Leese PJ, Weinbaum CM (2010) Community-based hepatitis B screening programs in the United States in 2008. J Viral Hepat 17: 28–33.
[39]
Rein DB, Lesesne SB, Smith BD, Weinbaum CM (2011) Models of community-based hepatitis B surface antigen screening programs in the U.S. and their estimated outcomes and costs. Public Health Rep 126: 560–567.
[40]
Institute of Medicine (2010) Hepatitis and liver cancer: A national strategy for prevention and control of hepatitis B and C. Washington: The National Academies Press. 252 p.
[41]
Cohen C, Holmberg SD, McMahon BJ, Block JM, Brosgart CL, et al. (2011) Is chronic hepatitis B being undertreated in the United States? J Viral Hepat 18: 377–383.
[42]
Ward JW, Averhoff FM, Koh HK (2011) World Hepatitis Day: a new era for hepatitis control. Lancet 378: 552–553.
